STANDARD BIOTOOLS INC.
LABCIK 0001162194 · Laboratory Analytical Instruments · Nasdaq
- FLUIDIGM CORP (until 2022-04-01)
Revenue (TTM)
$82.68M
−6.2% YoY
Q1 Mar 2026
Net Income (TTM)
$32.89M
+46.1% YoY
Q1 Mar 2026
EPS Diluted (TTM)
$0.08
+61.5% YoY
Q1 Mar 2026
Gross Margin
51.4%
Q1 Mar 2026
Operating Margin
-118.6%
Q1 Mar 2026
Net Margin
39.8%
Q1 Mar 2026
Free Cash Flow (TTM)
−$155.26M
Q1 Mar 2026
Cash
$265.77M
Q1 Mar 2026
Total Debt
$0
Q1 Mar 2026
Shares Outstanding
390.07M sh
Q1 Mar 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
Balance Sheet
Cash vs Debt
Latest news
All news →-
Routine Neutral
Standard BioTools (LAB) Adopts New Equity Incentive Plan
The company filed a new stock compensation plan effective June 17, 2026, pending shareholder approval.